![Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL](https://oncodaily.com/pub/uploads/2023/11/download-22-e1701200451814.jpg)
Photo of Paolo Tarantino from X
Mar 4, 2024, 17:58
Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
”You don’t always need a fancy new drug to impact patients QoL. In the D-TORCH phase 3 trial, the use of topical diclofenac during capecitabine reduced the risk of G2-3 HFS (3.8% vs 15%, p=0.03) and of HFS-related dose reductions. Should be considered SoC.”
Read further.
Source: Paolo Tarantino/X